Leerink Recent News
Wall Street Analysts Reflect On AT&T-Time Warner Ruling, Assess Implications Outside Tech, Media
Analysts Roar Praise For Aslan, But Leerink More Tepid
Leerink Downgrades Hologic After 'Lower Quality' Q2 Revenue Beat
Leerink Upgrades Mylan On Barrage Of Catalysts, Diversified Platforms
Leerink's Takeaways From CNBC's 'Healthy Returns' Conference
Leerin: Armo Biosciences' 'Promising' Data Justifies A Bullish Stance
Why Leerink Adjusted Upside Expectations For 3 Biotechs
AbbVie Shares Double In A Year; Leerink Moves To Sidelines
Leerink: Bluebird Bio's Catalysts Are Priced In
The CVS-Aetna Deal: The Sell Side Responds
Neurocrine Biosciences Exceeds Expectations With Ingrezza Launch
Buy Thermo Fisher On Amazon Fear-Inspired Dip
Express Scripts: Another Potential Amazon Victim?
Amazon Could Partner With UnitedHealth For Pharmacy Unit By Thanksgiving
Analyst: Amazon's Entry Into Pharmacy Is All But Certain At This Point
Selling The News In Acadia Pharmaceuticals
Pros And Cons Of All The News Out Of Acadia Pharma This Week
There's Good Cause To Be Excited About Amicus Therapeutics Clinical Program
What's The Thesis On ProQR Now, After Promising Phase 1 Data?
43% Upside Seen For Dova Pharma Following Competitor Product's Poor Results
The Street Has Finally Recognized The Exelixis Clinical Program Potential
Mirati Therapeutics Sitravatinib Data, Explained
Inside Align Technology's Q2 Beat And Raise: Teen Segment Could See An Inflection Point